About vivos therapeutics inc - VVOS
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.
VVOS At a Glance
Vivos Therapeutics, Inc.
7921 Southpark Plaza
Littleton, Colorado 80120
| Phone | 1-844-672-4357 | Revenue | 17.44M | |
| Industry | Medical Specialties | Net Income | -21,170,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 16.047% | |
| Fiscal Year-end | 12 / 2026 | Employees | 268 | |
| View SEC Filings |
VVOS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.196 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.736 |
| Enterprise Value to Sales | 1.85 |
| Total Debt to Enterprise Value | 0.418 |
VVOS Efficiency
| Revenue/Employee | 65,085.821 |
| Income Per Employee | -78,992.537 |
| Receivables Turnover | 11.033 |
| Total Asset Turnover | 0.863 |
VVOS Liquidity
| Current Ratio | 0.243 |
| Quick Ratio | 0.243 |
| Cash Ratio | 0.112 |
VVOS Profitability
| Gross Margin | 52.932 |
| Operating Margin | -114.051 |
| Pretax Margin | -121.711 |
| Net Margin | -121.367 |
| Return on Assets | -104.709 |
| Return on Equity | -655.012 |
| Return on Total Capital | -176.24 |
| Return on Invested Capital | -355.172 |
VVOS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 112.404 |
| Total Debt to Total Assets | 53.682 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 36.813 |